# Litigation Analytics Pointed at Hatch-Waxman

**Niche:** [[niches/pharmaceutical-manufacturers/paragraph-iv-first-to-file-launches/profile|Paragraph IV & First-to-File Launches]]
**Industry:** [[industries/pharmaceutical-manufacturers|Pharmaceutical Manufacturers]]
**Type:** Buy & Customize (Vertical Adaptation)
**One-liner:** Patent litigation analytics already track judges, counsel and outcomes; they do not model what a Paragraph IV case means for a generic launch date.
**Tags:** #large-language-models #bert #survival-analysis #feature-engineering #revenue-impact
**Contested on:** Every serious competitor in this niche is fighting to file a substantially complete Paragraph IV ANDA first and clear the brand's patents, and whoever converts the most first-to-file positions into day-one launches takes the account.

## The Problem
Generic makers need to know when a challenged patent will stop blocking launch: the likely ruling date, the odds by patent type and court, and how often similar cases settle with an entry date. Outside counsel give opinions; analytics tools give case statistics without the launch view.

## What Already Exists
Lex Machina, Docket Navigator and PACER-based tools track Hatch-Waxman cases by district, judge, counsel and outcome.

## The Customization Gap
The adaptation joins dockets to FDA data: the 30-month stay date, tentative approval status, other filers and their certifications, and Orange Book patent types (compound, formulation, method of use). It models time from suit to ruling or settlement and the probability of at-risk launch, per patent and molecule, and keeps privileged strategy separate from public analytics.

## Target Customer
In-house IP counsel and portfolio leads at generic makers.

## Impact If Solved
Launch dates forecast from case data rather than opinion would tighten API purchasing and inventory build for launch, where a few months' error ties up millions in stock (estimate).
